The Latest Analyst Ratings For AbbVie
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have updated their ratings on AbbVie (NYSE:ABBV), showing a positive trend with 2 bullish and 5 somewhat bullish ratings. The average 12-month price target for ABBV has been raised to $188.29, indicating a 4.44% increase from the previous target. Analysts from firms like Guggenheim, Raymond James, and Barclays have raised their price targets, reflecting optimism about AbbVie's future performance despite recent challenges in revenue growth and profitability metrics.
March 22, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie has received positive analyst ratings with an increased average price target of $188.29, reflecting a 4.44% rise. Despite facing a -5.42% decline in revenue growth and below-average profitability metrics, the updated analyst outlook suggests confidence in AbbVie's future performance.
The increase in AbbVie's average price target and the positive ratings from analysts indicate a bullish outlook for the stock. Despite the recent financial challenges, such as a decline in revenue growth and below-average profitability metrics, the analysts' optimism is based on AbbVie's strong product portfolio and market position. This suggests that the market may react positively in the short term, considering the analysts' influence and the upward revision of price targets.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100